Furthermore, the plausible variability in toxicity induced by GGPPS inhibitors to wild-type TP53 versus TP53 mutated AML cells has not been previously reported; such data may provide some insight as to the potential impact of TP53 mutations/alterations for the in vivo efficacy of GGPPS inhibitors. The gene discussed is TP53; the disease is acute myeloid leukemia.